Despite advances in treatment options, cancer remains a major health problem worldwide. The disease is characterized by the uncontrolled growth of abnormal cells whose ability to evade the immune system’s surveillance is a key factor in their proliferation and persistence.
In recent years, the field of immunotherapy, a form of cancer treatment utilizing the patients´ own immune system to specifically seek and destroy cancer cells, has significantly changed the standard of care in oncology and emerged as a major pillar in the treatment of cancer. Although immunotherapy has resulted in durable responses in some tumor types, a majority of cancers do not respond to current immunotherapeutic approaches.
Immatics believes that its differentiated approaches may address major challenges to cancer immunotherapy. The company’s roadmap is designed to impact a wide range of cancer types and patients with unmet medical need by overcoming challenges for effective cancer treatment with novel TCR-based product candidates.
Immatics’ approach towards the goal of opening new avenues of treatment for cancer patients starts with the discovery and validation of true targets (using the XPRESIDENT® platform). In the next step, Immatics identifies, engineers and validates delivering the power of T cells to cancer patients.
at a glance
Unlocking new T cell receptor-based immunotherapies by identifying true targets:
Immatics brings together a breadth of technologies matched with deep knowledge of cancer-specific targets and TCRs to achieve the next advance in immunotherapy.